In contrast to several authors who found hepatic cytochrome P 450 2D6 (CYP2D6) metabolising status to be clinically unimportant in treatment with the CYP2D6 substrate, risperidone, we report on a 17-year-old schizophrenic patient who suffered from severe extrapyramidal side effects (EPS) while being treated with risperidone at 4 mg per day. He was genotyped as a CYP2D6 poor metaboliser (PM). The active moiety of risperidone (sum of risperidone and 9-hydroxyrisperidone) was elevated and increased even further under co-medication with haloperidol and biperiden. We conclude that the PM phenotype for CYP2D6 of this patient had major clinical importance in treatment with risperidone. Most likely metabolic pathways other than CYP2D6 were also involved that are probably inhibited by haloperidol.
References
-
1
Bork J A, Rogers T, Wedlund P J, de Leon J.
A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A.
J Clin Psychiatry.
1999;
60
469-476
-
2
Chen S Q, Chou W H, Blouin R A, Mao Z P, Humphries L L, Meek C. et al .
The cytochrome P450 2D6 (CYP2D6) enzyme polymorphism: Screening costs and influence on clinical outcomes in psychiatry.
Clin Pharmacol Ther.
1996;
60
(5)
522-534
-
3
Eichelbaum M, Spannbrucker N, Steincke B, Dengler H J.
Defective N-oxidation of sparteine in man: a new pharmacogenetic defect.
Eur J Clin Pharmacol.
1979;
16
(3)
183-187
-
4
Eichelbaum M, Gross A S.
The genetic polymorphism of debrisoquine/sparteine metabolism-clinical aspects.
Pharmacol Ther.
1990;
46
(3)
377-394
-
5
Ereshefsky L.
Pharmacokinetics and drug interactions: update for new antipsychotics.
J Clin Psychiatry.
1996;
57
(11)
12-25
-
6
Fang J, Bourin M, Baker G B.
Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4.
Naunyn-Schmiedebergs-Arch-Pharmacol.
1999;
359
(2)
147-151
-
7
Griese E U, Zanger U M, Brudermanns U, Gaedigk A, Mikus G, Morike K. et al .
Assessment of the predictive power of genotypes for the in-vivo catalytic function of CYP2D6 in a German population.
Pharmacogenetics.
1998;
8
(1)
15-26
-
8
Huang M -L, van Peer A, Woestenborghs R, De Coster R, Heykants J, Jansen A AI. et al .
Pharmacokinetics of the novel antipsychotic agent risperidone and the prolactine response in healthy subjects.
Clin Pharmacol Ther.
1993;
54
257-268
-
9
Mahgoub A, Idle J R, Dring L G, Lancaster R, Smith R L.
Polymorphic hydroxylation of Debrisoquine in man.
Lancet.
1977;
2
(8038)
584-586
-
10 Risperdal [package insert]. Neuss, Germany: Janssen-Cilag GmbH 1999
-
11
Scordo M G, Spina E, Facciolà G, Avenoso A, Johansson I, Dahl M L.
Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone.
Psychopharmacology.
1999;
147
300-305
-
12
Spina E, Gitto C, Avenoso A, Campo G M, Caputi A P, Perucca E.
Relationship between plasma desipramine levels, CYP2D6 phenotype and clinical response to desipramine: a prospective study.
Eur J Clin Pharmacol.
1997;
51
(5)
395-398
-
13
Stüven T, Griese E -U, Kroemer H K, Eichelbaum M, Zanger U M.
Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction.
Pharmacogenetics.
1996;
6
417-421
-
14
Van Beijsterveldt L EC, Geerts R JF, Leysen J E, Megens A AHP, Van den Eynde H MJ, Meuldermans W EG. et al .
The regional brain distribution of risperidone and its active metabolite 9-hydroxy-risperidone in the rat.
Psychopharmacology.
1994;
114
53-62
-
15
Yasui N, Kondo T, Otani K, Furukori H, Mihara K, Suzuki A. et al .
Effects of itraconazole on the steady-state plasma concentrations of haloperidol and its reduced metabolite in schizophrenic patients: in vivo evidence of the involvement of CYP3A4 for haloperidol metabolism.
J Clin Psychopharmacol.
1999;
19
(2)
149-154
Dr. G. Barth
Universitätsklinik für Psychiatrie und Psychotherapie
Osianderstr. 22
72076 Tübingen
Germany
Email: gdbarth@med.uni-tuebingen.de
